[Genetic variation of IL-28B is associated with treatment response of patients with chronic hepatitis C].

Objective To explore the effect of IL-28B variation on the response of patients with chronic hepatitis C virus (HCV) infection to therapy.Methods A total of 220 patients with chronic hepatitis C (CHC) were prospectively treated with pegilated interferon (peg-IFN) in combination with ribavirin (RBV) for 48 weeks.After completing the therapy,the patients were followed-up for 24 weeks and the therapeutic effectiveness was evaluated.The rs8099917 was identified from each cohort.The IL28B genotype was compared in hepatitis C patients to assess the effect of single nucleotide polymorphism (SNP)on different treatment response.Result The proportion of the rs8099917 1T,TG,and GG genotypes was 71.4％,25.0％,and 3.6％ in sustained viral response (SVR) group; 15.8％,60.5％,23.7％ in null response (NR) group; 38.1％,52.3％,9.6％ in relapse (RP) group.There was a statistically significant difference in the genotype among SVR,NR and RP groups (P ＜0.001,Chi-square test).NR vs.SVR (TG vs.TT:OR =7.67,95％ CI:2.91-20.56,P＜0.001).RP va.SVR (TG vs.11:OR=3.10,95％ CI:1.14-6.36,P ＜ 0.01 ).Conclusions The genotypes of IL-28 B ( rs8099917 ) is closely related to the effectiveness of peg-IFN-α/RBV therapy,and it is an important predictive factor before treatment in patients with chronic hepatitis C. Key words: Hepatitis C, chronic; Interleukins; Polymorphism, single nucleotide; Recurrence